Results 121 to 130 of about 510,045 (326)
MECHANICAL CIRCULATORY SUPPORT: PROBLEMS, SOLUTIONS AND NEW DIRECTIONS
Вестник трансплантологии и искусственных органов, 2014 The article brings up for the discussion main problems standing in the way of development of the mechanical circulatory support (MCS) technology. We give a short historical overview of the development of this technology in our country. Classifi cation of
G. P. Itkin
doaj +1 more source
Molecular Oncology, EarlyView.This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain +3 more
wiley +1 more source
Mechanical Circulatory Support in High-Risk Percutaneous Coronary Intervention [PDF]
, 2021 The use of mechanical circulatory devices to support high-risk elective percutaneous coronary intervention (PCI) has become more common as the group of patients considered inoperable or high risk for surgical revascularization has grown. Most of the data
Alaswad, Khaldoon +3 more
core +1 more source
Data-Driven Simulator for Mechanical Circulatory Support with Domain Adversarial Neural Process [PDF]
arXivMechanical Circulatory Support (MCS) devices, implemented as a probabilistic deep sequence model. Existing mechanical simulators for MCS rely on oversimplifying assumptions and are insensitive to patient-specific behavior, limiting their applicability to real-world treatment scenarios.
arxiv
Molecular Oncology, EarlyView.Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma +9 more
wiley +1 more source
The Total Artificial Heart and the Dilemma of Deactivation [PDF]
, 2016 It is widely believed to be permissible for a physician to discontinue any treatment upon the request of a competent patient. Many also believe it is never permissible for a physician to intentionally kill a patient.
Bronner, Ben
core +1 more source
Sequential Pattern mining of Longitudinal Adverse Events After Left Ventricular Assist Device Implant [PDF]
arXiv, 2019 Left ventricular assist devices (LVADs) are an increasingly common therapy for patients with advanced heart failure. However, implantation of the LVAD increases the risk of stroke, infection, bleeding, and other serious adverse events (AEs). Most post-LVAD AEs studies have focused on individual AEs in isolation, neglecting the possible interrelation ...
arxiv
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
At the Heart of Innovation: Jefferson’s Heart Transplant Program [PDF]
, 2017 Jefferson’s Heart Transplant Program reactivated this year with a new, system-wide approach to heart failure that makes innovative, evidence-based, comprehensive care more accessible to patients throughout the Delaware Valley.
core +1 more source
Heart Rate Variability: A possible machine learning biomarker for mechanical circulatory device complications and heart recovery [PDF]
, 2020 Cardiovascular disease continues to be the number one cause of death in the United States, with heart failure patients expected to increase to \u3e8 million by 2030.
Aras, Shravan +2 more
core +1 more source